Publications

Filter by Year:2022 2020 2019 2018 2017

27-May-2022

Noxopharm announced a research abstract has been published at ASCO 2022 which confirms lead drug candidate, Veyonda’s immunomodulatory properties against nasopharyngeal carcinoma, in combination with the chemotherapy cisplatin.

Read More here.

27-Apr-2022

Noxopharm collaborators at Hudson confirm the relevance of TLR7 activation in Lupus validating the great potential of Noxopharm’s in-licenced molecules, comprising a new class of TLR7 inhibitors

Read More here.

8-Apr-2022

The reputable Journal of Nuclear Medicine published Noxopharm’s LuPIN trial as its featured article with its results pictured on the cover of the journal’s April edition.

¹⁷⁷ Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I/II Trial | Journal of Nuclear Medicine

1

Copyright © Noxopharm